Biotech Values

[jellybean]

If this is true, then this IMO will be the biggest hurdle for MNTA <<<<Most sales are in hospitals, so how long has S/A tied up the deals? >>>> Sales in hospitals are controlled by the P&T committees and MNTA's drug will have to be reviewed in each case. If you want to know how difficult a process that is, how entrenched a suppler (even of an inferior drug) can be, and finally, how quickly a current supplier can discount then look at the story of ZGEN and KG's thrombin.